A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorExcyte Biopharma Ltd
About this trial
This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.
Eligibility criteria
Qualifiers
Participants or their legally acceptable representative must sign an ICF indicating that the participants understand the purpose of, and procedures required for the study and are willing to participate in the study.
Diagnosis of multiple myeloma according to the IMWG criteria.
Receipt of at least two prior classes of drugs either in separate regimens or as combinations. The three classes are defined as: An immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 drug.
Serum M-protein ≥0.5 g/dL;
Disqualifiers
Plasma cell leukemia (>2.0×10^9/L plasma cells by standard differential), Waldenstrom's Macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary light-chain amyloidosis.
Targeted therapy with small molecule drug within 2 weeks or 5 half-lives, whichever is longer;
Targeted therapy with macromolecular drug or Immunomodulatory agent therapy within 2 weeks;
Chemotherapy within 2 weeks;
Trial design
Treatments tested in this trial
- YKST02
Treatment groups
70 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov